6-Day 5 Limit Up Minohua: Even if JH389 is successfully approved for non-drug products in the future, there are significant uncertainties regarding whether large-scale sales can be achieved.

Ask AI · Is Minovera’s stock price surge reflecting the market’s excessive optimism about JH389?

China Economic Net AI Express, March 27: Minovera (603538.SH) released a stock trading risk alert announcement on March 27, stating that the company has noticed that the market and some channels are discussing the company’s relevant research data, clinical trial progress, and future development plans. As of the submission date of this announcement, the company’s R&D product JH389 in the European region is currently in the safety trial phase and faces multiple uncertainties, including possible failure to pass the review, the need for additional research, and trial results falling short of expectations. Even if in the future JH389 is successfully approved for listing as a non-drug product, the global and domestic weight-loss-related markets have already shown a highly competitive landscape, with ample product supply. In the market, there are various GLP-1 weight-loss drugs, as well as a large number of non-drug products such as weight-loss health supplements, dietary supplements, meal replacements, and functional foods that widely participate in the competition. Whether the company can achieve large-scale sales in the future and whether it can generate stable revenue and profit contributions are both subject to major uncertainties. The company hereby solemnly reminds investors to fully consider the above risks, objectively and rationally view the progress of the company’s R&D project, and make investment decisions prudently.

China Economic Net Daily